Description de l'entreprise
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.
Conseil d'administration & Conseil de surveillance
| PDG |
| Jean-Jacques Bienaimé |
| Conseil d'administration |
| Brian Mueller, Amy Wireman, Dr. Brinda Balakrishnan, Dr. C. Greg Guyer, G. Eric Davis, Henry J. Fuchs, Jeff Ajer, Philip Lo Scalzo |
| Conseil de surveillance |
| Jean-Jacques Bienaimé, David Pyott, Dr. Dennis J. Slamon, Dr. Elaine J. Heron, Dr. V. Bryan Lawlis, Elizabeth Anderson, Mark Alles, Maykin Ho, Richard A. Meier, Robert Hombach, Willard H. Dere |
Données de l'entreprise
| Nom: |
Biomarin Pharmaceutical Inc. |
| Adresse: |
770 Lindaro Street,San Rafael, California 94901, USA |
| Téléphone: |
+1-415-506-6700 |
| Fax: |
+1-415-3827889 |
| Courriel: |
-
|
| Internet: |
www.bmrn.com/ |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
58.89% |
| IPO date: |
01/07/1999 |
Relations avec les investisseurs
| Nom: |
Traci McCarty |
| Téléphone IR: |
+1-415-455-7558 |
| IR-Fax: |
- |
| E-mail IR: |
IR@BMRN.com
|
